JP Morgan keeps Biohaven at "overweight" and raises its price target from $14 to $35
JP Morgan maintained its "overweight" rating on Biohaven and raised its price target from $14 to $35, an increase of 150.0%. The new target implies 171.3% upside from the November 18 close of $12.90. The three most recent analyst notes on Biohaven over the past 30 days set price targets between $21 and $32.
In 25 seconds
- JP Morgan reiterates its "overweight" rating on Biohaven.
- The price target rises from $14 to $35, a 150.0% increase.
- The new target implies 171.3% upside from the November 18 close of $12.90.
IASummary generated by artificial intelligence from a story by TradingView. It may contain errors: the original source prevails.





Comments
Be respectful. Comments reported by several people are hidden until a moderator reviews them.
You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.